N-Propargylamine-hydroxypyridinone hybrids as multitarget agents for the treatment of Alzheimer’s disease

Jianan Guo,Yujia Zhang,Changjun Zhang,Chuansheng Yao,Jingqi Zhang,Xiaoying Jiang,Zhichao Zhong,Jiamin Ge,Tao Zhou,Renren Bai,Yuanyuan Xie
DOI: https://doi.org/10.1016/j.bioorg.2021.105013
IF: 5.307
2021-08-01
Bioorganic Chemistry
Abstract:<p>AD is a progressive brain disorder. Because of the lack of remarkable single-target drugs against neurodegenerative disorders, the multitarget-directed ligand strategy has received attention as a promising therapeutic approach. Herein, we rationally designed twenty-nine hybrids of <em>N</em>-propargylamine-hydroxypyridinone. The designed hybrids possessed excellent iron-chelating activity (pFe<sup>3+</sup> = 17.09-22.02) and potent monoamine oxidase B inhibitory effects. Various biological evaluations of the optimal compound <strong>6b</strong> were performed step by step, including inhibition screening of monoamine oxidase (<em>h</em>MAO-B IC<sub>50</sub> = 0.083 ± 0.001 µM, <em>h</em>MAO-A IC<sub>50</sub> = 6.11 ± 0.08 µM; SI = 73.5), prediction of blood-brain barrier permeability and mouse behavioral research. All of these favorable results proved that the <em>N</em>-propargylamine-hydroxypyridinone scaffold is a promising structure for the discovery of multitargeted ligands for AD therapy.</p>
biochemistry & molecular biology,chemistry, organic
What problem does this paper attempt to address?